Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Answer. what the stock has done since uplisting is not relevant to the issue. What's relevant is the timeline it took to uplist and the fact it was a penny stock trading at .003 cent usd right before uplisting. It's a real world example that uplisting rules are not one size fits all. Once again, it should be reiterated that you could point to a million gazillion companies who uplist and the stock tanks below the target price like Facebook did with it's disastrous IPO. However, look at them now. On the flip side you have a million gazillion stocks that explode to the upside well beyond their uplisted target price and never look back like Tesla. IPO @ $17 and closed @ $24 and never looked back. Are those two extreme examples? Sure, but there's even more extreme examples of IPO successes and failures across the spectrum of stock sectors. The point being is that no two stories and circumstances are exactly alike. Most folks here default position is an uplist to NASDAQ will not support a Dollarville stock price. Much less supporting a Hundred Dollarville stock price. Thus, I would be remiss to not leave this message board without some Food For Thought On Thanksgiving Day:

@ www.fiercebiotech.com/biotech/biopharma-series-a-and-ipos-skyrocket-but-post-ipo-and-m-a-performance-down-1h21-report

Early biopharma investment nears $5B and IPOs are up, but newly public companies face sluggish performance:

report by Kyle LaHucik | Jul 23, 2021 8:21am


The most active investors in these early financings were Alexandria Venture Investments, which notched 12 deals, and Casdin Capital, which did nine. (Foremniakowski/GettyImages)

Early-stage biopharma investors were on their series A game in the first half of 2021 with nearly $5 billion in cash infusions, while every private biotech and their siblings wanted to hit the public markets.

Biopharma funding almost doubled year-over-year to $4.69 billion across the U.S. and Europe for the critical series A round, according to a new report by Silicon Valley Bank. The number of deals grew by a third compared to the first two quarters of 2020.

"Investment pace intensified in 2021, buoyed by the accelerated adoption of healthtech solutions and new care delivery models and a strong interest in emerging biopharma technologies," the authors wrote.

Investors were most interested in platform technology deals with biotechs that could potentially spit out multiple pipeline products over time. These deals racked up nearly half of the total haul with $2.2 billion in investment. Oncology biotechs came in second with $1.1 billion. Small molecule drugs won gold for most investor backing, antibodies took silver and gene therapies topped out the medal podium.

RELATED: Managed marketplaces and reality TV: How a new generation of gatekeepers are opening biotech up to amateur investors

Total biopharma funding reached $20.3 billion across the first half, which comes quite close to the $24.6 billion recorded for the entire previous year. To put biopharma investment dollars in context, the healthcare space benefited from a total $47 billion in cash infusions, which more than doubled the first half of 2020.

The most active investors in these early financings were Alexandria Venture Investments, which notched 12 deals, and Casdin Capital, which did nine. Big Pharmas Pfizer, Eli Lilly, Novartis, Sanofi, Takeda, AbbVie Johnson & Johnson, Bristol Myers and Roche were also big spenders. Pfizer had the most with 14 deals. Venture funds from Novartis and Novo Nordisk also got in the game.

IPO window open
A step above private funding comes the lauded public markets, and there was no shortage of activity there.

"Investors believe the IPO window will remain open," the report said. That prediction is based on mezzanine crossover activity in biopharma leading to 83 "likely IPO financings."

IPOs are a "driving force for exits" among biopharmas, with 25 listings in each quarter this year. 2021 has the potential to break last year's record 84 IPOs, but the investment bank predicts 80 for the year "as the market slows in 2H 2021."

RELATED: Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts

But it hasn't all been roses for the newly public biopharmas. Companies in the sector have had lackluster performances since listing, compared to good performance for diagnostics/tools and medical device makers. Valuations and dollars dipped from 2020's records.

IPOs aren't the only way to reach the Nasdaq. Don't forget about your favorite acronym, the SPAC, or special purpose acquisition company. Nautilus Biotechnology raised $345 million in gross proceeds from its merger with blank check company Arya Sciences III, and Nuvation Bio picked up about $646 million from its merger with Panacea Acquisition during the half.

Since 2020, 16 biopharmas have announced de-SPAC transactions and six have completed the process, including Nautilus, Nuvation Bio and NRx Pharmaceuticals. The average de-SPAC performance of those six is far in the red at negative 30%.

And, despite lofty sales for Big Pharma, M&A activity proved dismal. Shockingly, just seven private mergers and acquisitions in biopharma occurred between January and July, despite many major companies sitting on a powder keg of cash from COVID-19 therapeutics and vaccines.

RELATED: Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts

Four of the deals that did happen were pre-clinical companies, including Tidal Therapeutics and Arvelle Therapeutics, and the median upfront acquisition value was $305 million.

But we could see some blockbusters yet: Silicon Valley predicts biopharma will end 2021 with five or six $1 billion-plus private M&A deals.

@ seekingalpha.com/news/3624427-nuvation-bio-to-go-public-in-combination-blank-cheque-firm-panacea

Nuvation Bio to go public in combination with blank cheque firm Panacea
Oct. 21, 2020 3:40 PM ETNUVBBy: Vandana Singh, SA News Editor

Full stop

So what does either of the above articles mean from a reasonable perspective regarding Algernon Pharmaceuticals Inc? It’s my belief, although Algerrnon is a publicly traded company, the fact remains it’s still a young clinical stage biotech company. Those holding pennyland shares are taking on risks like Venture Capitalists. Albeit, pennylanders are less sophisticated in many respects. Nonetheless, pennylanders are positioned before the uplist to NASDAQ or NYSE (The Big Leagues). So what are some things we can glean from the world of biotech VC’s?

Every private biotech and their siblings want to hit the public markets (NASDAQ or NYSE)

Biopharma funding almost doubled year-over-year to $4.69 billion across the U.S. and Europe for the critical series A round.

Investors were most interested in platform technology deals with biotechs that could potentially spit out multiple pipeline products over time.

Small molecule drugs won gold for most investor backing, antibodies took silver and gene therapies topped out the medal podium.

Total biopharma funding reached $20.3 billion across the first half, which comes quite close to the $24.6 billion recorded for the entire previous year.

Big Pharmas Pfizer, Eli Lilly, Novartis, Sanofi, Takeda, AbbVie Johnson & Johnson, Bristol Myers and Roche were also big spenders.

Silicon Valley predicts biopharma will end 2021 with five or six $1 billion-plus private M&A deals.

Full stop

Did anyone notice this highlight from the article?

Small molecule drugs won gold for most investor backing, antibodies took silver and gene therapies topped out the medal podium.

If so, consider this from Algernon pharmaceuticals:

NP-120 Ifenprodil

The Company’s lead compound in its idiopathic pulmonary fibrosis (IPF) research program, is a drug called Ifenprodil, an orally delivered small molecule, which was originally developed by Sanofi to treat peripheral circulatory disorders. Algernon conducted two independent studies showing that NP-120 (Ifenprodil) outperformed the world’s leading two treatments for IPF, Nintedanib and Pirfenidone in a recent pre-clinical in vivo animal study, reducing fibrosis by 56% with statistical significance.

Did anyone notice this highlight from the article?

Investors were most interested in platform technology deals with biotechs that could potentially spit out multiple pipeline products over time.

If so, consider this from Algernon Pharmaceuticals:

Ifenprodil - Idiopathic Pulmonary Fibrosis (IPF)
Ifenprodil - Chronic Cough (CC)
Ifenprodil - Small Cell Lung Cancer (SCLC)
Ifenprodil - Pancreatic Cancer (PC)

Did I miss any targeted disease indications thus far?

The list of potential treatments with Ifenprodil will likely expand.

Does it place Algernon in a more or less attractive position with a move to NASDAQ?

The same can be said for the DMT Stroke Program.

NASDAQ will view things a lot differently than Pennyland.

Time will tell if any of it will equate to Hundred Dollarville or Shillingville.

W O R L D


M$